Pioglitazone and reductions in post-challenge glucose levels in patients with type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 8, Issue 1, 2006, Pages 31-38

  Khan, Mehmood ^a,b   Murray, F T ^a   Karunaratne, M ^a   Perez, A ^a  

^a TAKEDA PHARMACEUTICALS   (United States)

^b Takeda Global Research and Development Center Inc ^*  (United States)

Author keywords

Cardiovascular risk; Pioglitazone; Post challenge; Postprandial; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; PIOGLITAZONE; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG METABOLISM; DRUG TARGETING; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN DETERMINATION; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PARALLEL DESIGN; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; SINGLE BLIND PROCEDURE;

EID: 33646007967     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2005.00489.x     Document Type: Article

References (63)

1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2003. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2003.
2. American Diabetes Association. What is pre-diabetes? Available at: http://www.diabetes.org/pre-diabetes.jsp. Accessed September 30, 2004.
3. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004; 27: S5-S10.
4. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131: 281-303.
5. American Diabetes Association and National Institute of Diabetes, Digestive and Kidney Diseases. The prevention or delay of type 2 diabetes. Diabetes Care 2002; 25: 742-749.
6. Wei M, Gaskill SP, Haffner SM, Stern MP. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality: The San Antonio Heart Study. Diabetes Care 1998; 21: 1167-1172.
7. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853. Erratum in: Lancet 1999; 354: 602.
8. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.
9. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23 (Suppl. 2): B21-B29.
10. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004; 27 (Suppl. 1): S15-S35.
11. Gerich JE. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med 2003; 163: 1306-1316.
12. Haffner SM. American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care 2004; 27 (Suppl. 1): S68-S71.
13. Ceriello A. Impaired glucose tolerance and cardiovascular disease: The possible role of post-prandial hyperglycemia. Am Heart J 2004; 147: 803-807.
14. Del Prato S, Tiengo A. The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus. Diabetes Metab Res Rev 2001; 17: 164-174.
15. American Diabetes Association. Postprandial blood glucose. Diabetes Care 2001; 24: 775-778.
16. Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 1997; 20: 1822-1826.
17. Temelkova-Kurktschiev T, Koehler C, Henkel D, Leonhardt W, Fuecker K, Hanefeld M. Post challenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care 2000; 23: 1830-1834.
18. American Association of Clinical Endocrinologists. The American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus: The AACE system of intensive diabetes self-management-2002 update. Endocr Pract 2002; 8 (Suppl. 1): 41-82.
19. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 2004; 27 (Suppl. 1): S11-S14.
20. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: A 6-month randomized placebo- controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000; 23: 1605-1611.
21. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: A randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000; 22: 1395-1409.
22. Miyazaki Y, Mahankali A, Matsuda M et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001; 24: 710-719.
23. Scherbaum WA, Goke B, German Pioglitazone Study Group. Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: A double-blind, placebo-controlled study. Horm Metab Res 2002; 34: 589-595.
24. Wallace TM, Levy JC, Matthews DR. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. Diabet Med 2004; 21: 568-576.
25. Miyazaki Y, Matsuda M, DeFronzo RA. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 2002; 25: 517-523.
26. Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE, Pioglitazone 026 Study Group. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001; 12: 413-423.
27. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes. JAMA 2002; 287: 360-372.
28. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-1197.
29. Dunnett CW. New tables for multiple comparisons with a control. Biometrics 1964; 20: 482-491.
30. Gibaldi M, Perrier D. Pharmacokinetics, 2nd edn. New York: Marcel Dekker, 1982; 445-449.
31. Heine RJ, Balkau B, Ceriello A, Del Prato S, Horton ES, Taskinen MR. What does postprandial hyperglycemia mean? Diabet Med 2004; 21: 208-213.
32. Bonora E, Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: The epidemiological evidence. Diabetologia 2001; 44: 2107-2114.
33. Hanefeld M. Postprandial hyperglycaemia: Noxious effects on the vessel wall. Int J Clin Pract 2002; 129: 45-50.
34. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. Br Med J 2000; 321: 405-412.
35. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12. 4 years Diabetes Care 1999; 22: 233-240.
36. Hanefeld M, Fischer S, Julius U et al. Risk factors for myocardial infarction and death in newly detected NIDDM: The Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996; 39: 1577-1583.
37. Donahue RP, Abbott RD, Reed DM, Yano K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes 1987; 36: 689-692.
38. Saydah SH, Miret M, Sung J, Varas C, Gause D, Brancati FL. Postchallenge hyperglycemia and mortality in a national sample of U. S Adults. Diabetes Care 2001; 24: 1397-1402.
39. Balkau B, Shipley M, Jarrett RJ et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998; 21: 360-367.
40. De Vegt F, Dekker JM, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ. Similar 9-year mortality risks and reproducibility for the World Health Organization and American Diabetes Association glucose tolerance categories: The Hoorn Study. Diabetes Care 2000; 23: 40-44.
41. Lowe LP, Liu K, Greenland P, Metzger BE, Dyer AR, Stamler J. Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men. The Chicago Heart Association Detection Project in Industry Study. Diabetes Care 1997; 20: 163-169.
42. Barrett-Connor E, Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study. Diabetes Care 1998; 21: 1236-1239.
43. Shaw JE, Hodge AM, De Courten M, Chitson P, Zimmet PZ. Isolated post-challenge hyperglycemia confirmed as a risk factor for mortality. Diabetologia 1999; 42: 1050-1054.
44. Wahl PW, Savage PJ, Psaty BM, Orchard TJ, Robbins JA, Tracy RP. Diabetes in older adults: Comparison of 1997 American Diabetes Association classification of diabetes mellitus with 1985 WHO classification. Lancet 1998; 352: 1012-1015.
45. Hu G, Qiao Q, Tuomilehto J, Eliasson M, Feskens EJ, Pyorala K, DECODE Insulin Study Group. Plasma insulin and cardiovascular mortality in non-diabetic European men and women: A meta-analysis of data from eleven prospective studies. Diabetologia 2004; 47: 1245-1256.
46. Haffner SM. The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease. Endocr Rev 1998; 19: 583-592.
47. Lyons TJ. Lipoprotein glycation and its metabolic consequences. Diabetes 1992; 41 (Suppl. 2): 67-73.
48. King GL, Wakasaki H. Theoretical mechanisms by which hyperglycemia and insulin resistance could cause cardiovascular diseases in diabetes. Diabetes Care 1999; 22 (Suppl. 3): C31-C37.
49. Kopprasch S, Pietzsch J, Kuhlisch E et al. In vivo evidence for increased oxidation of circulating LDL in impaired glucose tolerance. Diabetes 2002; 51: 3102-3106.
50. Pietzsch J, Julius U, Nitzsche S, Hanefeld M. In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance. Diabetes 1998; 47: 1928-1934.
51. Laws A, Reaven GM. Insulin resistance and risk factors for coronary heart disease. Baillieres Clin Endocrinol Metab 1993; 7: 1063-1078.
52. Hanefeld M, Koehler C, Schaper F, Fuecker K, Henkel E, Temelkova-Kurktschiev T. Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals. Atherosclerosis 1999; 144: 229-235.
53. Hanefeld M, Koehler C, Henkel E, Fuecker K, Schaper F, Temelkova-Kurktschiev T. Post-challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intima-media thickness: The RIAD Study. Risk factors in impaired glucose tolerance for atherosclerosis and diabetes. Diabet Med 2000; 17: 835-840.
54. Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschiev T. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 2004; 35: 1073-1078.
55. Chiasson JL, Josse RG, Gomis R et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM trial. JAMA 2003; 290: 486-494.
56. Winkler K, Konrad T, Füllert S et al. Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: A double-blind, placebo-controlled study. Diabetes Care 2003; 26: 2588-2594.
57. Ishibashi M, Egashira K, Hiasa K et al. Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension 2002; 40: 687-693.
58. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. Rapid communication: Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 3452-3456.
59. Collins AR, Meehan WP, Kintscher U et al. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2001; 21: 365-371.
60. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2000; 106: 523-531.
61. Herz M, Johns D, Reviriego J et al. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. Clin Ther 2003; 25: 1074-1095.
62. Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S. Pioglitazone 014 Study Group. Efficacy and safety of pioglitazone in type 2 diabetes: A randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 2002; 56: 251-257.
63. Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A, PROactive Study Group. The prospective pioglitazone clinical trial in macrovascular events (PROactive): Can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 2004; 27: 1647-1653.